Anti-fibrotic effects of curcumin and some of its analogues in the heart

  • Armita Mahdavi Gorabi
  • Saeideh Hajighasemi
  • Nasim Kiaie
  • Giuseppe M. C. Rosano
  • Thozhukat Sathyapalan
  • Khalid Al-Rasadi
  • Amirhossein SahebkarEmail author


Cardiac fibrosis stems from the changes in the expression of fibrotic genes in cardiac fibroblasts (CFs) in response to the tissue damage induced by various cardiovascular diseases (CVDs) leading to their transformation into active myofibroblasts, which produce high amounts of extracellular matrix (ECM) proteins leading, in turn, to excessive deposition of ECM in cardiac tissue. The excessive accumulation of ECM elements causes heart stiffness, tissue scarring, electrical conduction disruption and finally cardiac dysfunction and heart failure. Curcumin (Cur; also known as diferuloylmethane) is a polyphenol compound extracted from rhizomes of Curcuma longa with an influence on an extensive spectrum of biological phenomena including cell proliferation, differentiation, inflammation, pathogenesis, chemoprevention, apoptosis, angiogenesis and cardiac pathological changes. Cumulative evidence has suggested a beneficial role for Cur in improving disrupted cardiac function developed by cardiac fibrosis by establishing a balance between degradation and synthesis of ECM components. There are various molecular mechanisms contributing to the development of cardiac fibrosis. We presented a review of Cur effects on cardiac fibrosis and the discovered underlying mechanisms by them Cur interact to establish its cardio-protective effects.


Curcumin Diferuloylmethane C66 J19 Cardiac fibrosis 


Funding information

Financial support was from the National Institute for Medical Research Development (NIMAD), Tehran, Iran (Grant no: 943771).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interests.

Ethics approval

Not applicable.

Informed consent

Not applicable.


  1. 1.
    Grimaldi V, De Pascale MR, Zullo A, Soricelli A, Infante T, Mancini FP, Napoli C (2017) Evidence of epigenetic tags in cardiac fibrosis. J Cardiol 69(2):401–408CrossRefGoogle Scholar
  2. 2.
    Russo I, Frangogiannis NG (2016) Diabetes-associated cardiac fibrosis: cellular effectors, molecular mechanisms and therapeutic opportunities. J Mol Cell Cardiol 90:84–93. CrossRefGoogle Scholar
  3. 3.
    Tao H, Shi K-H, Yang J-J, Huang C, Liu L-P, Li J (2013) Epigenetic regulation of cardiac fibrosis. Cell Signal 25(9):1932–1938CrossRefGoogle Scholar
  4. 4.
    Wang NP, Wang ZF, Tootle S, Philip T, Zhao ZQ (2012) Curcumin promotes cardiac repair and ameliorates cardiac dysfunction following myocardial infarction. Br J Pharmacol 167(7):1550–1562CrossRefGoogle Scholar
  5. 5.
    van Putten S, Shafieyan Y, Hinz B (2016) Mechanical control of cardiac myofibroblasts. J Mol Cell Cardiol 93:133–142. CrossRefGoogle Scholar
  6. 6.
    Creemers EE, van Rooij E (2016) Function and therapeutic potential of noncoding RNAs in cardiac fibrosis. Circ Res 118(1):108–118CrossRefGoogle Scholar
  7. 7.
    Micheletti R, Plaisance I, Abraham BJ, Sarre A, Ting C-C, Alexanian M, Maric D, Maison D, Nemir M, Young RA (2017) The long noncoding RNA Wisper controls cardiac fibrosis and remodeling. Sci Transl Med 9(395):eaai9118CrossRefGoogle Scholar
  8. 8.
    Xiao J, Sheng X, Zhang X, Guo M, Ji X (2016) Curcumin protects against myocardial infarction-induced cardiac fibrosis via SIRT1 activation in vivo and in vitro. Drug design, development and therapy 10:1267Google Scholar
  9. 9.
    Kunnumakkara AB, Bordoloi D, Padmavathi G, Monisha J, Roy NK, Prasad S, Aggarwal BB (2017) Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. Br J Pharmacol 174(11):1325–1348CrossRefGoogle Scholar
  10. 10.
    Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendía LE, Sahebkar A (2017) Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial. Drug Res 67(4):244–251.
  11. 11.
    Rezaee R, Momtazi AA, Monemi A, Sahebkar A (2017) Curcumin: A potentially powerful tool to reverse cisplatin-induced toxicity. Pharmacol Res 117:218–227.
  12. 12.
    Karimian MS, Pirro M, Majeed M, Sahebkar A (2017) Curcumin as a natural regulator of monocyte chemoattractant protein-1. Cytokine Growth F R 33:55–63. CrossRefGoogle Scholar
  13. 13.
    Sahebkar A, Cicero AFG, Simental-Mendia LE, Aggarwal BB, Gupta SC (2016) Curcumin downregulates human tumor necrosis factor-alpha levels: a systematic review and meta-analysis ofrandomized controlled trials. Pharmacol Res 107:234–242. CrossRefGoogle Scholar
  14. 14.
    Wongcharoen W, Phrommintikul A (2009) The protective role of curcumin in cardiovascular diseases. Int J Cardiol 133(2):145–151CrossRefGoogle Scholar
  15. 15.
    Fang G, Chen S, Huang Q, Chen L, Liao D (2018) Curcumin suppresses cardiac fibroblasts activities by regulating the proliferation and cell cycle via the inhibition of the p38 MAPK/ERK signaling pathway. Mol Med Rep 18(2):1433–1438Google Scholar
  16. 16.
    Meng Z, Yu X-h, Chen J, Li L, Li S (2014) Curcumin attenuates cardiac fibrosis in spontaneously hypertensive rats through PPAR-γ activation. Acta Pharmacol Sin 35(10):1247CrossRefGoogle Scholar
  17. 17.
    Leask A (2010) Potential therapeutic targets for cardiac fibrosis: TGFβ, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 106(11):1675–1680CrossRefGoogle Scholar
  18. 18.
    Valente AJ, Sakamuri SS, Siddesha JM, Yoshida T, Gardner JD, Prabhu R, Siebenlist U, Chandrasekar B (2013) TRAF3IP2 mediates interleukin-18-induced cardiac fibroblast migration and differentiation. Cell Signal 25(11):2176–2184CrossRefGoogle Scholar
  19. 19.
    Zhao T, Zhao W, Chen Y, Li VS, Meng W, Sun Y (2013) Platelet-derived growth factor-D promotes fibrogenesis of cardiac fibroblasts. Am J Phys Heart Circ Phys 304(12):H1719–H1726Google Scholar
  20. 20.
    Shimosawa T (2013) Salt, the renin–angiotensin–aldosterone system and resistant hypertension. Hypertens Res 36(8):657CrossRefGoogle Scholar
  21. 21.
    de Cavanagh EM, Ferder M, Inserra F, Ferder L (2009) Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint. Am J Phys Heart Circ Phys 296(3):H550–H558Google Scholar
  22. 22.
    Siddesha JM, Valente AJ, Sakamuri SS, Yoshida T, Gardner JD, Somanna N, Takahashi C, Noda M, Chandrasekar B (2013) Angiotensin II stimulates cardiac fibroblast migration via the differential regulation of matrixins and RECK. J Mol Cell Cardiol 65:9–18. CrossRefGoogle Scholar
  23. 23.
    Crowley MJ, Powers BJ, Myers ER, McBroom AJ, Sanders GD (2012) Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treatment of ischemic heart disease: future research needs prioritization. Am Heart J 163(5):777–782 e778 CrossRefGoogle Scholar
  24. 24.
    Ghosh AK, Vaughan DE (2012) PAI-1 in tissue fibrosis. J Cell Physiol 227(2):493–507CrossRefGoogle Scholar
  25. 25.
    Weisberg AD, Albornoz F, Griffin JP, Crandall DL, Elokdah H, Fogo AB, Vaughan DE, Brown NJ (2005) Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol 25(2):365–371CrossRefGoogle Scholar
  26. 26.
    Khan R, Sheppard R (2006) Fibrosis in heart disease: understanding the role of transforming growth factor-β1 in cardiomyopathy, valvular disease and arrhythmia. Immunology 118(1):10–24CrossRefGoogle Scholar
  27. 27.
    Hein S, Arnon E, Kostin S, Schönburg M, Elsässer A, Polyakova V, Bauer EP, Klövekorn W-P, Schaper J (2003) Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 107(7):984–991CrossRefGoogle Scholar
  28. 28.
    Ghosh AK, Varga J (2007) The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. J Cell Physiol 213(3):663–671CrossRefGoogle Scholar
  29. 29.
    Daniels A, Van Bilsen M, Goldschmeding R, Van Der Vusse G, Van Nieuwenhoven F (2009) Connective tissue growth factor and cardiac fibrosis. Acta Physiol 195(3):321–338CrossRefGoogle Scholar
  30. 30.
    Gao D-F, Niu X-L, Hao G-H, Peng N, Wei J, Ning N, Wang N-P (2007) Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells––role of PPAR-γ in vascular fibrosis. Biochem Pharmacol 73(2):185–197CrossRefGoogle Scholar
  31. 31.
    Derosa G, Maffioli P (2012) Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk. Curr Mol Pharmacol 5(2):272–281CrossRefGoogle Scholar
  32. 32.
    Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM (2013) PPARγ signaling and metabolism: the good, the bad and the future. Nat Med 19(5):557CrossRefGoogle Scholar
  33. 33.
    Wei W-Y, Zhang N, Li L-L, Ma Z-G, Xu M, Yuan Y-P, Deng W, Tang Q-Z (2018) Pioglitazone alleviates cardiac fibrosis and inhibits endothelial to mesenchymal transition induced by pressure overload. Cell Physiol Biochem 45(1):26–36CrossRefGoogle Scholar
  34. 34.
    Singh RM, Cummings E, Pantos C, Singh J (2017) Protein kinase C and cardiac dysfunction: a review. Heart Fail Rev 22(6):843–859CrossRefGoogle Scholar
  35. 35.
    Huang K-P (1989) The mechanism of protein kinase C activation. Trends Neurosci 12(11):425–432CrossRefGoogle Scholar
  36. 36.
    Singh RK, Kumar S, Gautam PK, Tomar MS, Verma PK, Singh SP, Acharya A (2017) Protein kinase C-α and the regulation of diverse cell responses. Biomolecular concepts 8(3–4):143–153Google Scholar
  37. 37.
    Roberts AC, Porter KE (2013) Cellular and molecular mechanisms of endothelial dysfunction in diabetes. Diabetes and Vascular Disease Research 10(6):472–482CrossRefGoogle Scholar
  38. 38.
    Davis J, Molkentin JD (2014) Myofibroblasts: trust your heart and let fate decide. J Mol Cell Cardiol 70:9–18CrossRefGoogle Scholar
  39. 39.
    Cicero AFG, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, Fras Z, Katsiki N, Langlois M, Latkovskis G, Panagiotakos DB, Paragh G, Mikhailidis DP, Mitchenko O, Paulweber B, Pella D, Pitsavos C, Reiner Z, Ray KK, Rizzo M, Sahebkar A, Serban MC, Sperling LS, Toth PP, Vinereanu D, Vrablík M, Wong ND, Banach M (2017) Lipid-lowering nutraceuticals in clinical practice: position paper from an international lipid expert panel. Nutr Rev 75(9):731–767. CrossRefGoogle Scholar
  40. 40.
    Panahi Y, Khalili N, Sahebi E, Namazi S, Karimian MS, Majeed M, Sahebkar A (2017) Antioxidant effects of curcuminoids in patients with type 2 diabetes mellitus: a randomized controlled trial. Inflammopharmacology 25(1):25–31. CrossRefGoogle Scholar
  41. 41.
    Sahebkar A, Cicero AFG, Simental-Mendía LE, Aggarwal BB, Gupta SC (2016) Curcumin downregulates human tumor necrosis factor-α levels: a systematic review and meta-analysis ofrandomized controlled trials. Pharmacol Res 107:234–242. CrossRefGoogle Scholar
  42. 42.
    Liu W, Zhai Y, Heng X, Che FY, Chen W, Sun D, Zhai G (2016) Oral bioavailability of curcumin: problems and advancements. J Drug Target 24(8):694–702CrossRefGoogle Scholar
  43. 43.
    Hagl S, Kocher A, Schiborr C, Kolesova N, Frank J, Eckert GP (2015) Curcumin micelles improve mitochondrial function in neuronal PC12 cells and brains of NMRI mice - impact on bioavailability. Neurochem Int 89:234–242. CrossRefGoogle Scholar
  44. 44.
    Sandhir R, Yadav A, Mehrotra A, Sunkaria A, Singh A, Sharma S (2014) Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington's disease. NeuroMolecular Med 16(1):106–118. CrossRefGoogle Scholar
  45. 45.
    Chojnacki JE, Liu K, Yan X, Toldo S, Selden T, Estrada M, Rodríguez-Franco MI, Halquist MS, Ye D, Zhang S (2014) Discovery of 5-(4-hydroxyphenyl)-3-oxo-pentanoic acid [2-(5-methoxy-1H-indol-3-yl)-ethyl]-amide as a neuroprotectant for Alzheimer's disease by hybridization of curcumin and melatonin. ACS Chem Neurosci 5(8):690–699. CrossRefGoogle Scholar
  46. 46.
    Chang CZ, Wu SC, Lin CL, Kwan AL (2015) Curcumin, encapsulated in nano-sized PLGA, down-regulates nuclear factor kappaB (p65) and subarachnoid hemorrhage induced early brain injury in a rat model. Brain Res 1608:215–224. CrossRefGoogle Scholar
  47. 47.
    Jayaraj RL, Tamilselvam K, Manivasagam T, Elangovan N (2013) Neuroprotective effect of CNB-001, a novel pyrazole derivative of curcumin on biochemical and apoptotic markers against rotenone-induced SK-N-SH cellular model of Parkinson's disease. Journal of molecular neuroscience : MN 51(3):863–870. CrossRefGoogle Scholar
  48. 48.
    Mythri RB, Harish G, Dubey SK, Misra K, Bharath MM (2011) Glutamoyl diester of the dietary polyphenol curcumin offers improved protection against peroxynitrite-mediated nitrosative stress and damage of brain mitochondria in vitro: implications for Parkinson's disease. Mol Cell Biochem 347(1–2):135–143. CrossRefGoogle Scholar
  49. 49.
    Pan Y, Wang Y, Zhao Y, Peng K, Li W, Wang Y, Zhang J, Zhou S, Liu Q, Li X (2014) Inhibition of JNK phosphorylation by a novel curcumin analog prevents high glucose–induced inflammation and apoptosis in cardiomyocytes and the development of diabetic cardiomyopathy. Diabetes 63(10):3497–3511CrossRefGoogle Scholar
  50. 50.
    Chen HJ, Yang X, Lu KQ, Lu C, Zhao YJ, Zheng SQ, Li JL, Huang ZJ, Huang Y, Zhang YL, Liang G (2017) Inhibition of high glucose-induced inflammation and fibrosis by a novel curcumin derivative prevents renal and heart injury in diabetic mice. Toxicol Lett 278:48–58. CrossRefGoogle Scholar
  51. 51.
    Li KF, Zhai MG, Jiang LQ, Song F, Zhang B, Li J, Li H, Li BY, Xia L, Xu L, Cao Y, He MS, Zhu HZ, Zhang LY, Liang HL, Jin ZX, Duan WX, Wang SW (2019) Tetrahydrocurcumin ameliorates diabetic cardiomyopathy by attenuating high glucose-induced oxidative stress and fibrosis via activating the SIRT1 pathway. Oxidative Med Cell Longev 2019:Artn 6746907. Google Scholar
  52. 52.
    Tang Y, Bao M, Yang B, Zhang Y, Zhang B, Zhou Q, Chen J, Huang C (2009) Curcumin attenuates left ventricular dysfunction and remodeling in rabbits with chronic heart failure. Zhonghua xin xue guan bing za zhi 37(3):262–267Google Scholar
  53. 53.
    Nakayama N, Nakamura T, Okada H, Iwaki S, Sobel BE, Fujii S (2011) Modulators of induction of plasminogen activator inhibitor type-1 in HepG2 cells by transforming growth factor-β. Coron Artery Dis 22(7):468–478CrossRefGoogle Scholar
  54. 54.
    Liu H, Liu A, Shi C, Li B (2016) Curcumin suppresses transforming growth factor-β1-induced cardiac fibroblast differentiation via inhibition of Smad-2 and p38 MAPK signaling pathways. Experimental and therapeutic medicine 11(3):998–1004CrossRefGoogle Scholar
  55. 55.
    Zeng C, Zhong P, Zhao Y, Kanchana K, Zhang Y, Khan ZA, Chakrabarti S, Wu L, Wang J, Liang G (2015) Curcumin protects hearts from FFA-induced injury by activating Nrf2 and inactivating NF-κB both in vitro and in vivo. J Mol Cell Cardiol 79:1–12CrossRefGoogle Scholar
  56. 56.
    Soetikno V, Sari FR, Sukumaran V, Lakshmanan AP, Mito S, Harima M, Thandavarayan RA, Suzuki K, Nagata M, Takagi R (2012) Curcumin prevents diabetic cardiomyopathy in streptozotocin-induced diabetic rats: possible involvement of PKC–MAPK signaling pathway. Eur J Pharm Sci 47(3):604–614CrossRefGoogle Scholar
  57. 57.
    Guo S, Meng XW, Yang XS, Liu XF, Ou-Yang CH, Liu C (2018) Curcumin administration suppresses collagen synthesis in the hearts of rats with experimental diabetes. Acta Pharmacol Sin 39(2):195–204. CrossRefGoogle Scholar
  58. 58.
    Bugyei-Twum A, Advani A, Advani SL, Zhang Y, Thai K, Kelly DJ, Connelly KA (2014) High glucose induces Smad activation via the transcriptional coregulator p300 and contributes to cardiac fibrosis and hypertrophy. Cardiovasc Diabetol 13(1):89. CrossRefGoogle Scholar
  59. 59.
    Chung CC, Kao YH, Liou LP, Chen YJ (2014) Curcumin suppress cardiac fibroblasts activities by regulating proliferation, migration, and the extracellular matrix. Acta Cardiologica Sinica 30(5):474–482Google Scholar
  60. 60.
    Kim YS, Kwon JS, Cho YK, Jeong MH, Cho JG, Park JC, Kang JC, Ahn Y (2012) Curcumin reduces the cardiac ischemia–reperfusion injury: involvement of the toll-like receptor 2 in cardiomyocytes. J Nutr Biochem 23(11):1514–1523CrossRefGoogle Scholar
  61. 61.
    Yu W, Wu J, Cai F, Xiang J, Zha W, Fan D, Guo S, Ming Z, Liu C (2012) Curcumin alleviates diabetic cardiomyopathy in experimental diabetic rats. PLoS One 7(12):e52013. CrossRefGoogle Scholar
  62. 62.
    Sunagawa Y, Sono S, Katanasaka Y, Funamoto M, Hirano S, Miyazaki Y, Hojo Y, Suzuki H, Morimoto E, Marui A (2014) Optimal dose-setting study of curcumin for improvement of left ventricular systolic function after myocardial infarction in rats. J Pharmacol Sci 126(4):329–336CrossRefGoogle Scholar
  63. 63.
    Pang X-F, Zhang L-H, Bai F, Wang N-P, Garner RE, McKallip RJ, Zhao Z-Q (2015) Attenuation of myocardial fibrosis with curcumin is mediated by modulating expression of angiotensin II AT1/AT2 receptors and ACE2 in rats. Drug design, development and therapy 9:6043Google Scholar
  64. 64.
    Allen S, Liu YG, Scott E (2016) Engineering nanomaterials to address cell-mediated inflammation in atherosclerosis. Regen Eng Transl Med 2(1):37–50. CrossRefGoogle Scholar
  65. 65.
    Liu R, Zhang H, Yang J, Wang J, Liu J, Li C (2018) Curcumin alleviates isoproterenol-induced cardiac hypertrophy and fibrosis through inhibition of autophagy and activation of mTOR. Eur Rev Med Pharmacol Sci 22(21):7500–7508Google Scholar
  66. 66.
    Ozawa H, Imaizumi A, Sumi Y, Hashimoto T, Kanai M, Makino Y, Tsuda T, Takahashi N, Kakeya H (2017) Curcumin β-D-glucuronide plays an important role to keep high levels of free-form curcumin in the blood. Biol Pharm Bull 40(9):1515–1524CrossRefGoogle Scholar
  67. 67.
    Schiborr C, Eckert GP, Rimbach G, Frank J (2010) A validated method for the quantification of curcumin in plasma and brain tissue by fast narrow-bore high-performance liquid chromatography with fluorescence detection. Anal Bioanal Chem 397(5):1917–1925CrossRefGoogle Scholar
  68. 68.
    Feng T, Wei Y, Lee RJ, Zhao L (2017) Liposomal curcumin and its application in cancer. Int J Nanomedicine 12:6027–6044. CrossRefGoogle Scholar
  69. 69.
    Tsuda T (2018) Curcumin as a functional food-derived factor: degradation products, metabolites, bioactivity, and future perspectives. Food Funct 9(2):705–714CrossRefGoogle Scholar
  70. 70.
    Mirzaei H, Shakeri A, Rashidi B, Jalili A, Banikazemi Z, Sahebkar A (2017) Phytosomal curcumin: a review of pharmacokinetic, experimental and clinical studies. Biomed Pharmacother 85:102–112. CrossRefGoogle Scholar
  71. 71.
    Wang Y, Zhou S, Sun W, McClung K, Pan Y, Liang G, Tan Y, Zhao Y, Liu Q, Sun J (2014) Inhibition of JNK by novel curcumin analog C66 prevents diabetic cardiomyopathy with a preservation of cardiac metallothionein expression. American Journal of Physiology-Endocrinology and Metabolism 306(11):E1239–E1247CrossRefGoogle Scholar
  72. 72.
    Li C, Miao X, Lou Y, Lu Z, Adhikari BK, Wang Y, Liu Q, Sun J, Wang Y (2018) Cardioprotective effects of the novel curcumin analogue C66 in diabetic mice is dependent on JNK 2 inactivation. J Cell Mol Med 22(12):6314–6326CrossRefGoogle Scholar
  73. 73.
    Bugyei-Twum A, Abadeh A, Thai K, Zhang Y, Mitchell M, Kabir G, Connelly KA (2016) Suppression of NLRP3 Inflammasome activation ameliorates chronic kidney disease-induced cardiac fibrosis and diastolic dysfunction. Sci Rep 6:39551. CrossRefGoogle Scholar
  74. 74.
    Sunagawa Y, Morimoto T, Wada H, Takaya T, Katanasaka Y, Kawamura T, Yanagi S, Marui A, Sakata R, Shimatsu A, Kimura T, Kakeya H, Fujita M, Hasegawa K (2011) A natural p300-specific histone acetyltransferase inhibitor, curcumin, in addition to angiotensin-converting enzyme inhibitor, exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats. Circ J 75(9):2151–2159. CrossRefGoogle Scholar
  75. 75.
    Ma J, Ma S-y, Ding C-h (2017) Curcumin reduces cardiac fibrosis by inhibiting myofibroblast differentiation and decreasing transforming growth factor β1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinase 1. Chin J Integr Med 23(5):362–369CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Armita Mahdavi Gorabi
    • 1
  • Saeideh Hajighasemi
    • 2
  • Nasim Kiaie
    • 1
  • Giuseppe M. C. Rosano
    • 3
  • Thozhukat Sathyapalan
    • 4
  • Khalid Al-Rasadi
    • 5
    • 6
  • Amirhossein Sahebkar
    • 7
    • 8
    • 9
    Email author
  1. 1.Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran Heart CenterTehran University of Medical SciencesTehranIran
  2. 2.Department of Medical Biotechnology, Faculty of ParamedicineQazvin University of Medical SciencesQazvinIran
  3. 3.Department of Medical SciencesRomeItaly
  4. 4.Department of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical SchoolUniversity of HullHullUK
  5. 5.Medical Research CentreSultan Qaboos UniversityMuscatOman
  6. 6.Department of Biochemistry, College of Medicine and Health SciencesSultan Qaboos UniversityMuscatOman
  7. 7.Neurogenic Inflammation Research CenterMashhad University of Medical SciencesMashhadIran
  8. 8.Biotechnology Research Center, Pharmaceutical Technology InstituteMashhad University of Medical SciencesMashhadIran
  9. 9.School of PharmacyMashhad University of Medical SciencesMashhadIran

Personalised recommendations